SMAD3 and neoplasm: Wild-type tumours exhibited readily detectable PO4-SMAD3 activity, whereas mutant tumours showed significantly reduced PO4-SMAD3 activity (Fig. 4c and Supplementary Fig. 6), consistent with our observation that mutation of TGFβ receptors results in loss of canonical SMAD signalling activity.